Join us at noon ET for a Post-Hoc Live to discuss Hims & Hers' punchy decision to launch a compounded version of Novo Nordisk's Wegovy pill. Can Hims get away with it? What legal recourse does Novo have? Drew Armstrong and Endpoints' senior health tech reporter Shelby Livingston will discuss these and other points with Edgar Asebey, a partner at law firm Frier Levitt who works on compounding and FDA issues. You can set a calendar reminder here.